Skip to content
StockMarketAgent
Direct answer
ELV trades against a final fair-value range of $411.38-$853.64, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $411, high $854, with mid-point at $632.
Stock analysis

ELV ELV fair value $411–$854

ELV
By StockMarketAgent.AI team· supervised by
已分析: 2026-05-13下次更新: 2026-08-13Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
股价
$381.75
▲ +250.57 (+65.64%)
公允价值
$632
$411–$854
评级
强力买入
confidence 77/100
上行空间
+65.6%
upside to fair value
安全边际
$537.47
MoS level · 15%
市值
$82.9B
P/E fwd 13.1
英文原文ZH
翻译期间显示英文原文
此报告尚未翻译。翻译队列赶上后请在几分钟内刷新。

§1 执行摘要

  • Composite fair value $632 with high case $854.
  • Implied upside of 65.6% to fair value.
  • Moat 9/10 · confidence 77/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$632
Margin of safety
+39.6%
Confidence
77/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$381.75Price
Low $411.38
Mid $632.32
High $853.64

ELV trades against a final fair-value range of $411.38-$853.64, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Scale advantages driven by a
    Scale advantages driven by a massive member base in Anthem.
  • Network effects within the integrated
    Network effects within the integrated Anthem and Carelon ecosystems.
  • Bull thesis
    Massive margin of safety with implied -6.18% perpetual growth at the current price.

§2 看空情景

A severe scenario where elevated MLR persists due to structural shifts in medical utilization, compounded by adverse Medicare rate changes, significantly compressing operating margins below their historical norms.

该论点可能失败的方式

Unchecked Medical Cost Inflation

· Medium

Sustained elevated medical utilization drives MLR structurally higher, compressing operating margins permanently below historical averages.

FV impact
-35%
Trigger
12-24 Months

Severe Regulatory Reimbursement Cuts

· Low

Aggressive legislative action slashes Medicare Advantage and Medicaid reimbursement rates, effectively stunting top-line growth.

FV impact
-25%
Trigger
24-36 Months

Carelon Growth Stagnation

· Medium

Intense PBM competition limits Carelon's ability to win new external mandates, stalling the long-term margin-expansion thesis.

FV impact
-15%
Trigger
12-18 Months
需关注的早期预警信号
指标当前触发阈值
Medical loss ratio sequentially rising above targeted corridors.MonitorDeterioration versus the report thesis
Regulatory announcements of tighter Medicare funding.MonitorDeterioration versus the report thesis
Stalling growth or mandate losses in the Carelon segment.MonitorDeterioration versus the report thesis
Operating margins dipping below the 5.0% normalized threshold.MonitorDeterioration versus the report thesis
Material reduction in projected share repurchase pacing.MonitorDeterioration versus the report thesis

§3 财务历史

损益表 — 最近六期
项目T−0T−1T−2T−3T−4CAGR
期间2021-12-312022-12-312023-12-312024-12-312025-12-31Trend
营业收入$156.60B$171.34B$176.81B$199.13B+6.2%
毛利
营业利润
净利润$5.89B$5.99B$5.98B$5.66B-1.0%
每股收益(摊薄)$24.81$25.22$25.68$25.21+0.4%
EBITDA
研发
销售管理费用$15.91B$17.69B+2.7%

质量评分

OCF / 净利润
0.76×
>1 表示盈利质量高
会计质量门槛
Fail
经行业调整门槛
ROIC
8.4%
投入资本回报率
第 3 节

Numbers analysis

现金流

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

资本配置

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

个人订阅用户 — §4 及之后还有 11 个章节

阅读完整分析 — 还有 11 个章节。

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

涵盖每个股票的完整报告
24 个月的评级存档
关注列表简报 + 评级变更提醒
以任意语言导出 PDF + DOCX
开始免费试用
可随时取消。
FAQ

ELV — frequently asked questions

  1. Based on our latest analysis, ELV looks meaningfully undervalued. The current price is $382 versus a composite fair-value midpoint of $632 (range $411–$854), which implies roughly 65.6% upside to the midpoint.
Related coverage

Names readers of ELV also follow

Same archetype: mature-compounder